Earnings call transcript: Nolato Q3 2026 sales rise as margins narrow

Nolato's Q3 2026 earnings call revealed a 7% rise in sales to SEK 2.5 billion, driven by growth in its medical business and materials unit. However, profitability suffered as margins narrowed to 10.5% from 11.7% a year earlier. Adjusted EBITA fell to SEK 262 million, a 4.4% decline. The decline was attributed to ramp-up costs, raw-material timing effects, and weaker automotive demand.

Medical Solutions rose 9% organically, led by drug delivery, diagnostics, cardiology, and pharma packaging. Materials business posted a 27% organic growth and remained a key profit driver. Nolato completed two medical acquisitions and sold its Romanian unit as it reshaped its portfolio. Shares remained flat at $56.7 in premarket trading, near the middle of its 52-week range.